Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 10, 2022
Asensus Surgical, Inc. (NYSE American: ASXC) announced plans to release its third-quarter financial and operational results for 2022 after market hours on November 10, 2022. A conference call will occur at 4:30 p.m. ET on the same day to discuss these results, with a simultaneous webcast available. Asensus focuses on transforming surgical practices through its Senhance Surgical System, aiming for superior outcomes in Performance-Guided Surgery. Their technology integrates machine vision and deep learning to address current shortcomings in surgical procedures.
- Plans to release Q3 2022 financial results on November 10, indicating transparency and engagement with investors.
- Focus on Performance-Guided Surgery may enhance surgical outcomes and position the company as a leader in medical technology.
- No financial metrics or operational performance details provided before the earnings release, leading to uncertainty for investors.
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2022 third quarter financial and operating results after the market closes on Thursday, November 10, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial 1-866-652-5200 for domestic callers and 1-412-317-6060 for international callers, and reference conference ID 10171489 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available on the Company’s website.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.
Follow Asensus
- Email Alerts: https://ir.asensus.com/email-alerts
- LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
- Twitter: https://twitter.com/AsensusSurgical
- YouTube: https://www.youtube.com/c/transenterix
- Vimeo: https://vimeo.com/asxc
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
OR
MEDIA CONTACT:
Lauren Stredler, 847-271-6891
CG Life
lstredler@cglife.com
FAQ
When will Asensus Surgical release its third quarter financial results for 2022?
What time will the conference call for Asensus Surgical's Q3 results take place?
How can I access the conference call for Asensus Surgical's financial results?
What is the ticker symbol for Asensus Surgical?
